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Abstract
Background: Vitiligo is the most prevalent pigmentary disorder which occurs worldwide, with an incidence rate
between 0.1-4 percent. It is anticipated that the discovery of biological pathways of vitiligo pathogenesis will
provide novel therapeutic and prophylactic targets for future approaches to the treatment and prevention of
vitiligo. The purposes of this study were evaluating the efficacy of supplemental zinc on the treatment of vitiligo.
Methods: This randomized clinical trial was conducted for a period of one year. Thirty five patients among 86
participants were eligible to entrance to the study. The patients in two equal randomized groups took topical
corticosteroid and combination of oral zinc sulfate-topical corticosteroid.
Results: The mean of responses in the corticosteroid group and the zinc sulfate-corticosteroid combination group
were 21.43% and 24.7%, respectively.
Conclusion: Although, the response to corticosteroid plus zinc sulfate was more than corticosteroid, there was no
statistically significant difference between them. It appeared that more robust long-term randomized controlled
trials on more patients, maybe with higher doses of zinc sulfate, are needed to fully establish the efficacy of oral
zinc in management of vitiligo.
Trial Registration: chiCTRTRC10000930
Background
Vitiligo has been known for thousands of years because
of its visually phenotype [1,2]. It is characterized by
acquired, idiopathic, progressive, circumscribed hypome-
lanosis of the skin and hair, with total absence of mela-
nocytes microscopically [3].
Vitiligo is the most prevalent pigmentary disorder,
occurs worldwide [4], with an incidence rate between
0.1-2% [4-8], irrespective of age, race [4,7-9], ethnic ori-
gin, or skin color [10]. Both sexes are equally afflicted
[4]. In some studies, a female preponderance has been
reported [2,4,11], but the discrepancy has been attribu-
ted to a presumed increase in reporting of cosmetic
concerns by female patients [4]. Vitiligo commonly
begins in childhood or young adulthood [4,12], with
peak onset of 10 to 30 years [4,13], but it can develop at
any age [4,14-17].
It is generally agreed that there is an absence of func-
tional melanocytes in vitiligo skin and that this loss of
histochemically recognizable melanocytes is the result of
destruction [18]. The etiopathogenesis of vitiligo is com-
plex, and includes genetic factors, autoimmune process,
infectious factors, and psychological factors (stress and
personality characteristics of patients) [19].
Zinc is one of the important trace elements related to
health and disease [20]. Zinc in combination with other
micronutrients such as copper, cobalt, nickel, iron, man-
ganese, and calcium [21] plays an important role in the
process of melanogenesis [3,21]. With searching the
computerized bibliographic database Pub Med, we * Correspondence: nooshinbagherani@yahoo.com
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which motivated us to carry out this study.
Methods
This clinical trial was conducted for a period of one year
from March of 2008 till March of 2009. Eighty six viti-
ligo patients from 102 patients who attended the Der-
matology Center of Jundishapur University of Medical
Sciences participated in the study. The Jundishapour
University of Medical Sciences Ethical Committee per-
mission was obtained before performing the study. The
informed consent was prepared including the definition
of vitiligo, traditional therapeutic approaches and their
efficacy and safety, the process of trial and the probable
complication of zinc as a therapeutic new approach.
According to this consent, the patients could deny the
study whenever the drug complication was intolerable
for them.
At first, a questionnaire was completed for each
patient, which included the data of demographic status,
duration of vitiligo, medical and drug history, familial
status for vitiligo and pregnancy status in females. Then,
for all participants, laboratory tests were recommended
which comprised complete blood count and differentia-
tion of white blood cells, fasting blood sugar, serum cal-
cium, phosphorus and zinc levels, liver function (AST,
ALT, Alk Ph and Bil), renal function (BUN, Creatinin),
and thyroid function tests (T3, T4, TSH and T3RUP),
urinalysis and stool examination.
In the second step, among the patients, the eligible
ones who had inclusion criteria (Table. 1), were selected;
The eligible patients for continuing the second step
were randomized in two treatment groups. The first
group took topical corticosteroid as 0.05% clobetasol
propionate cream in isopropyl alcohol 65° preparation
(in equal proportion) for the body and 0.1% triamcino-
lone acetonide cream for the face and flexures, two
times daily. For the second group, topical corticosteroid
(compatible with the first group) admixed with oral zinc
sulfate (220-mg capsule) in dose of 2 capsules per day
in teenager and adults and 10 mg/kg of capsule or syrup
for children, were prescribed. For the second group,
serum zinc level was repeatedly measured 1 and 3 months
after commencing the treatment.
All patients were assessed 1, 3 and 4 months after
beginning the treatment. For comparing, we considered
the largest patch as the target lesion. This target patch
was selected in the way that lesions in exposed area and
distal parts of limbs were not included as target lesions;
so we omitted the probable bias in evaluation of
response regarding to probable more rapid response in
exposed areas or slower response in the hairless areas of
extremities. The surface of the target lesion was mea-
sured by two physicians with a crossed sheet and a
photograph was prepared for the next comparing. At
the next stages, we determined the response rate regard-
ing to the size of the target lesion.
Eventually, using the software of SPSS (Version 15),
results were analyzed. P value < 0.05 was considered to
be statistically significant.
Results
A total of 86 patients with vitiligo were studied. Among
these patients, 39 (45.3%) were female and 47 (54.7%)
were male. Totally, 39 (45.3%) of the patients had
abnormal laboratory tests, who were excluded from con-
tinuing study. The serum zinc were increased in 4
(4.7%) patients, and decreased in 9 (10.5%) patients.
According to the results with considering the inclu-
sion criteria, out of the 86 patients, 35 were eligible for
continuing the study. Then, the patients were divided in
two groups, randomly; randomization in the two groups
of therapy and control was performed by computerized
number tables. The first group receiving topical corti-
costeroid included 16 (45.7%) subjects, and the second
group receiving topical corticosteroid plus oral zinc sul-
fate was consistent of 19 (54.3%) subjects.
Considering the two treatment groups based on the
sex frequency, using Pearson Chi-Square test with P-
value of 0.45, showed no statistically significant
difference.
The minimum, maximum and mean of age in the first
group were 13.0, 57.0 and 32.2 (± 12.58), respectively,
and for the second group were 11.0, 59.0 and 30.5 (±
12.11), respectively. Comparing the two treatment
groups, in the view of age, with T-test and P-value of >
0.05 showed no statistically significant difference.
In the aspect of vitiligo involvement, using T-test and
P-value of 0.8, no significant difference was seen between
the two groups. The mean of involvement was 11.0% (±
6.6%) of body surface in the first group, whereas was
10.6% (± 8.1%) of the body surface in the second group.
In the first group, one patient (6.3%), and in the sec-
ond group also one patient (5.3%) showed decreased
Table 1 The inclusion criteria for entrance to the study
Any age
Any gender
The localized and gneralized types of vitiligo with exception of
segmental one (with involvement <20% of body surface)
Vitiligo duration less than 5 years
Negative history of systemic disorder
No pregnancy
Negative history of drug administration
Normal or low serum zinc
Normal other laboratory tests
Taking no zinc during 4 weeks prior to referring
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view of serum zinc level, there was no statistical signifi-
cance according to Fisher’s exact test and P-value of
1.00.
From the first group, one patient (6.3%) was excluded
from the study because of discontinuing the drug. In
second group, 3 patients (15.8%), because of refuting
reference, and one case (5.3%), because of rising of
s e r u mz i n cl e v e l ,w e r ee x c l u d e df r o mt h es t u d y .S o ,i n
both of the two groups, 15 patients continued the study
to the end of forth month. In the first group, out of
15 patients, one (6.3%) showed no response during
4m o n t h so ft h es t u d y ,c o n s i d e r i n gw i t hF i s h e r ’se x a c t
test and P-value of 1.00, had no statistically significance.
Both of the two groups showed no response during
the first month of the therapy. The mean of responses
in the third and forth months, in the first group were
19.3% (± 9.3%) and 21.43% (± 11.6%), respectively and
for the second group, were 20.8% (± 8.7%) and 24.7% (±
11.0%), respectively (Table 2). Although, the response in
the second group were more than the first group, T-test
revealed no statistically significant differences between
the two groups, in the third and forth months with P-
values equal to 0.6 and 0.4, respectively. To conclude,
topical corticosteroid plus oral zinc sulfate had no pre-
ference on topical corticosteroid only.
In the view of the complication of zinc sulfate, only 2
(13.3%) patients of the second group complained of a
little tolerable gastric burning.
Discussion
Vitiligo is an acquired depigmenting disorder due to loss
of melanocytes and the resultant absence of pigment
production affecting skin and mucosal surfaces [5], with
a prevalence of about 1-4% [22-24].
Although neither life threatening, nor symptomatic
(except that depigmented patches burn easily when
exposed to the sun) the effect of vitiligo can be cosmeti-
cally and psychologically devastating, resulting in low
self-esteem, poor body image, and difficulties in sexual
relationships [10,25]. It is a frustrating condition to
treat, spontaneous repigmentation occurs in more than
15% to 25% of cases [12]. Sun protection of the vitiligi-
nous areas with sunblocks is important [9,11], which
help prevent sunburn and thus may lessen photodamage
as well as the chance that a Koebner phenomenon will
occur. Sunscreens also decrease tanning of the unin-
volved skin and therefore lessen the contrast with vitili-
ginous lesions [4]. Cosmetic improvement can be
achieved by camouflage products and self-tanning dyes
[9].
Because the disease is still not understood, there is a
plethora of different treatments including topical corti-
costeroids, calcineurin inhibitors, vitamin-D derivatives,
phototherapy (ultraviolet [UV] A, narrowband UVB),
photochemotherapy (psoralen plus UVA [PUVA], psora-
len with sunlight [PUVAsol]), surgical techniques
[4,7,10,14,18,26,27], excimer laser [4,7,9,14,18,26-28], topi-
cal prostaglandin E (PGE2) [7], and combinations of topi-
cal therapies and light treatment [10]. Complementary
therapies have also been used, the most interesting being
ginkgo biloba [10], and levamisole [29] which have been
reported to have immune-modulating properties [10].
Pseudocatalase cream with Dead Sea climatotherapy are
also compatible with repigmentation [10]. Topical fluor-
ouracil [30], topical melagenina I and II, minoxidil [7],
oral L-phenylalanine [10,31-34], homeopathy, ayurvedic
medicine, climtologic, and balneologic therapies [7] are as
alternative therapy for vitiligo.
Zinc is one of the important trace elements related to
health and disease [35]. Essentiality of zinc is related
mainly to its function as the metal moiety of important
enzymes [3]. The most important of these processes are
cellular respiration, cellular utilization of oxygen, DNA
and RNA reproduction, maintenance of cell membrane
integrity, and sequestration of free radicals [36].
Zinc in combination with other micronutrients such
as copper, cobalt, nickel, iron, manganese, and calcium
[21] plays an important role in the process of melano-
genesis [3,21]. They catalyze the rearrangement of dopa-
chrome to form 5,6-dihydroxy indole-2 carboxylic acid
(DICA) [3,21], and enhancement of eumelanin polymer
formation from monomers [21]. This process is at the
final stage of eumelanin formation in melanogenesis
[21].
The most frequent adverse effects of zinc salts given
orally are gastrointestinal and include abdominal pain,
dyspepsia, nausea, vomiting, diarrhea, gastric irritation,
and gastritis [37].
There are few controlled trials assessing efficacy of
natural health products (e.g. vitamins, minerals, herbal
medicines and other supplements) for vitiligo, but those
that have been published generally show weakly positive
outcomes with few adverse reactions [14]. On the other
hand, with searching the computerized bibliographic
database Pub Med, we found no study of zinc efficacy in
Table 2 The mean of responses in third and forth months
in the two drug-prescribed groups, who continued
treatment till the end of the study
Group Month Number Mean of response (%) SD
First * Third 15 19.13 9.36
Second** Third 15 20.83 8.72
First Forth 15 21.43 11.64
Second Forth 15 24.70 11.04
*topical corticosteroid.
**oral zinc sulfate-topical corticosteroid combination.
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first one to investigate zinc efficacy in the treatment of
vitiligo.
Analysis of the zinc level in the study of Shameer et al
revealed a reduced level in 21.6% of the patients. Only
one patient showed elevated level of zinc. In this study,
the serum zinc level in the control group was within the
normal range. This differences between two groups was
statistically significant (P < 0.0002) [3]. In another study,
Arora et al showed that serum zinc was lower in vitiligo
patients than control group, but this difference was not
statistically important [20]. In our study, the serum zinc
l e v e lw e r en o r m a li n7 3( 8 4 . 9 % ) ,i n c r e a s e di n4( 4 . 7 % ) ,
and decreased in 9 (10.5%) of the patients. Unfortu-
nately, we had no control group for comparing the
serum zinc level. In spite of these, our study compared
with Shameer’s one, revealed lower frequency of reduced
serum zinc level and higher frequency of increased
serum zinc level.
This study showed that the response to the oral zinc
sulfate-topical corticosteroid combination was more
than the topical corticosteroid alone, but T-test revealed
no statistically significant difference between them.
Conclusion
We conclude that topical corticosteroid plus oral zinc
sulfate had no preference on topical corticosteroid only.
Considering the more effect of corticosteroid plus zinc
sulfate compared with corticosteroid alone, it appears
that more robust long-term randomized controlled trials
with more patients, maybe with higher doses of zinc sul-
fate, are needed to fully establish the efficacy of oral zinc
in management of vitiligo.
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